SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161971

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161971

gRNA Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Introduction

The gRNA Market supplies the guide RNA molecules that direct CRISPR gene-editing systems to precise locations in the genome. Guide RNA is the component that gives CRISPR its targeting ability, so every editing experiment, screening campaign and therapeutic programme depends on reliable, well-characterised guides. As gene editing moves from laboratory research into drug discovery, cell engineering, agriculture and clinical treatment, demand for high-quality guide RNA continues to rise. In 2026, the market is valued at US$400 Mn and is projected to reach US$900 Mn by 2033, registering a CAGR of 12.30%.

The market includes single guide RNA, two-part crRNA-tracrRNA formats, guide RNA libraries, and custom design and synthesis services. Products are offered in research grade, high-purity preclinical grade and GMP grade to suit different stages of development. Customers include academic and government research institutes, biotechnology and pharmaceutical companies, contract development and manufacturing organisations, and agricultural and industrial biotechnology firms, each with distinct requirements for purity, documentation and supply volume.

Market Insights

The market is segmented by product type, grade, application and end user. Single guide RNA combines targeting and scaffold sequences in one molecule and is widely used for its convenience, while two-part crRNA-tracrRNA systems offer flexibility for certain workflows. Guide RNA libraries support large-scale pooled screening, and custom design and synthesis services help customers obtain sequences and chemical modifications tailored to specific projects.

Revenue is shifting toward GMP-grade material and custom synthesis as more programmes advance toward the clinic. Research grade products remain essential for discovery work, while high-purity preclinical grade serves the transition stage before human studies. Applications span basic research and target discovery, drug discovery and screening, cell line engineering and bioproduction, therapeutic development and clinical manufacture, and agricultural biotechnology. Competition is moving away from price alone and toward documentation, chemistry expertise and supply assurance, since clinical developers need consistent quality and traceable records. The approvals of CRISPR therapies in 2023 and 2024 and regulatory guidance on gene-editing products have reinforced these expectations across the industry.

Drivers

The movement of CRISPR programmes into GMP clinical manufacture is the strongest driver of the market, with a high impact over the medium term. As therapeutic candidates progress through clinical trials and toward commercial use, developers need guide RNA produced under strict quality systems, with full documentation and batch-to-batch consistency. GMP material carries far higher value than research-grade product, so each programme that advances increases spending per project.

The expansion of pooled CRISPR screening in drug discovery is a medium-impact driver in the short term. Pharmaceutical and biotechnology companies use large guide RNA libraries to identify drug targets, understand disease biology and study resistance mechanisms, which creates repeat demand for libraries and custom synthesis. Restraints provide context. Delivery limits outside the liver and ex vivo cell therapies have a high long-term impact, restricting the range of diseases that editing therapies can currently address. Off-target assessment and characterisation requirements also lengthen qualification and release timelines, adding cost and complexity to clinical supply.

Business Opportunity

Dedicated GMP oligonucleotide capacity is one of the most valuable opportunities in the market. Clinical and commercial gene-editing programmes require guide RNA made in facilities with appropriate quality systems, validated processes and robust documentation. Supply of this material is specialised, and developers place high value on partners who can deliver consistent quality on reliable timelines. Suppliers that invest in dedicated GMP production lines, analytical capabilities and regulatory support can access a high-value supply pool where long-term relationships and supply assurance matter more than price.

Agricultural and industrial genome editing offers a second, non-clinical revenue pool. Crop developers use gene editing to improve yield, resilience and quality traits, while industrial biotechnology companies engineer microbes and cell lines for more efficient production of chemicals, enzymes and materials. These customers need guide RNA in substantial volumes, often with different specifications from clinical users. By serving this segment, suppliers can diversify revenue beyond human therapeutics and reduce their exposure to the timelines and risks associated with clinical development programmes.

Region Analysis

North America is the leading region in the gRNA Market with a 44% share. The region hosts a large concentration of gene-editing companies, academic research centres and clinical programmes, along with strong funding for life sciences research. These factors support high demand for research-grade, preclinical and GMP guide RNA.

Europe holds 27%, supported by strong academic research, an active biotechnology sector and growing clinical work in gene and cell therapies. Asia Pacific accounts for 21% and is the fastest-growing region at a 15.4% CAGR, driven by increasing research investment, expanding biotechnology industries, growth in contract development and manufacturing services, and rising use of genome editing in agriculture. Latin America represents 4% of the market, with demand coming mainly from academic research and agricultural biotechnology applications. The Middle East and Africa also hold 4%, where investment in research institutions and emerging biotechnology initiatives is gradually building demand. Across all regions, the shift toward GMP-grade supply and custom synthesis is raising the value of each order.

Key Players

  • Integrated DNA Technologies
  • Synthego Corporation
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Revvity, Inc.
  • Aldevron
  • Twist Bioscience Corporation
  • TriLink BioTechnologies

Segmentation

By Product Type:

  • Single Guide RNA
  • Two-Part crRNA-tracrRNA
  • Guide RNA Libraries
  • Custom Design and Synthesis Services

By Grade:

  • Research Grade
  • High-Purity Preclinical Grade
  • GMP Grade

By Application:

  • Basic Research and Target Discovery
  • Drug Discovery and Screening
  • Cell Line Engineering and Bioproduction
  • Therapeutic Development and Clinical Manufacture
  • Agricultural Biotechnology

By End User:

  • Academic and Government Research Institutes
  • Biotechnology and Pharmaceutical Companies
  • Contract Development and Manufacturing Organisations
  • Agricultural and Industrial Biotechnology Companies

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global gRNA Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global gRNA Market Outlook, 2020-2033

  • 3.1. Global gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 3.1.1. Single Guide RNA
    • 3.1.2. Two-Part crRNA-tracrRNA
    • 3.1.3. Guide RNA Libraries
    • 3.1.4. Custom Design and Synthesis Services
  • 3.2. Global gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 3.2.1. Research Grade
    • 3.2.2. High-Purity Preclinical Grade
    • 3.2.3. GMP Grade
  • 3.3. Global gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 3.3.1. Basic Research and Target Discovery
    • 3.3.2. Drug Discovery and Screening
    • 3.3.3. Cell Line Engineering and Bioproduction
    • 3.3.4. Therapeutic Development and Clinical Manufacture
    • 3.3.5. Agricultural Biotechnology
  • 3.4. Global gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 3.4.1. Academic and Government Research Institutes
    • 3.4.2. Biotechnology and Pharmaceutical Companies
    • 3.4.3. Contract Development and Manufacturing Organisations
    • 3.4.4. Agricultural and Industrial Biotechnology Companies
  • 3.5. Global gRNA Market Outlook, by Region, Value (US$ Mn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America gRNA Market Outlook, 2020-2033

  • 4.1. North America gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 4.1.1. Single Guide RNA
    • 4.1.2. Two-Part crRNA-tracrRNA
    • 4.1.3. Guide RNA Libraries
    • 4.1.4. Custom Design and Synthesis Services
  • 4.2. North America gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 4.2.1. Research Grade
    • 4.2.2. High-Purity Preclinical Grade
    • 4.2.3. GMP Grade
  • 4.3. North America gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 4.3.1. Basic Research and Target Discovery
    • 4.3.2. Drug Discovery and Screening
    • 4.3.3. Cell Line Engineering and Bioproduction
    • 4.3.4. Therapeutic Development and Clinical Manufacture
    • 4.3.5. Agricultural Biotechnology
  • 4.4. North America gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 4.4.1. Academic and Government Research Institutes
    • 4.4.2. Biotechnology and Pharmaceutical Companies
    • 4.4.3. Contract Development and Manufacturing Organisations
    • 4.4.4. Agricultural and Industrial Biotechnology Companies
  • 4.5. North America gRNA Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 4.5.1. U.S. gRNA Market Outlook, by Product Type, 2020-2033
    • 4.5.2. U.S. gRNA Market Outlook, by Grade, 2020-2033
    • 4.5.3. U.S. gRNA Market Outlook, by Application, 2020-2033
    • 4.5.4. U.S. gRNA Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada gRNA Market Outlook, by Product Type, 2020-2033
    • 4.5.6. Canada gRNA Market Outlook, by Grade, 2020-2033
    • 4.5.7. Canada gRNA Market Outlook, by Application, 2020-2033
    • 4.5.8. Canada gRNA Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe gRNA Market Outlook, 2020-2033

  • 5.1. Europe gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 5.1.1. Single Guide RNA
    • 5.1.2. Two-Part crRNA-tracrRNA
    • 5.1.3. Guide RNA Libraries
    • 5.1.4. Custom Design and Synthesis Services
  • 5.2. Europe gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 5.2.1. Research Grade
    • 5.2.2. High-Purity Preclinical Grade
    • 5.2.3. GMP Grade
  • 5.3. Europe gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 5.3.1. Basic Research and Target Discovery
    • 5.3.2. Drug Discovery and Screening
    • 5.3.3. Cell Line Engineering and Bioproduction
    • 5.3.4. Therapeutic Development and Clinical Manufacture
    • 5.3.5. Agricultural Biotechnology
  • 5.4. Europe gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 5.4.1. Academic and Government Research Institutes
    • 5.4.2. Biotechnology and Pharmaceutical Companies
    • 5.4.3. Contract Development and Manufacturing Organisations
    • 5.4.4. Agricultural and Industrial Biotechnology Companies
  • 5.5. Europe gRNA Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 5.5.1. Germany gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.2. Germany gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.3. Germany gRNA Market Outlook, by Application, 2020-2033
    • 5.5.4. Germany gRNA Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.6. Italy gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.7. Italy gRNA Market Outlook, by Application, 2020-2033
    • 5.5.8. Italy gRNA Market Outlook, by End User, 2020-2033
    • 5.5.9. France gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.10. France gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.11. France gRNA Market Outlook, by Application, 2020-2033
    • 5.5.12. France gRNA Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.14. U.K. gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.15. U.K. gRNA Market Outlook, by Application, 2020-2033
    • 5.5.16. U.K. gRNA Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.18. Spain gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.19. Spain gRNA Market Outlook, by Application, 2020-2033
    • 5.5.20. Spain gRNA Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.22. Russia gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.23. Russia gRNA Market Outlook, by Application, 2020-2033
    • 5.5.24. Russia gRNA Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe gRNA Market Outlook, by Product Type, 2020-2033
    • 5.5.26. Rest of Europe gRNA Market Outlook, by Grade, 2020-2033
    • 5.5.27. Rest of Europe gRNA Market Outlook, by Application, 2020-2033
    • 5.5.28. Rest of Europe gRNA Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific gRNA Market Outlook, 2020-2033

  • 6.1. Asia Pacific gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 6.1.1. Single Guide RNA
    • 6.1.2. Two-Part crRNA-tracrRNA
    • 6.1.3. Guide RNA Libraries
    • 6.1.4. Custom Design and Synthesis Services
  • 6.2. Asia Pacific gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 6.2.1. Research Grade
    • 6.2.2. High-Purity Preclinical Grade
    • 6.2.3. GMP Grade
  • 6.3. Asia Pacific gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 6.3.1. Basic Research and Target Discovery
    • 6.3.2. Drug Discovery and Screening
    • 6.3.3. Cell Line Engineering and Bioproduction
    • 6.3.4. Therapeutic Development and Clinical Manufacture
    • 6.3.5. Agricultural Biotechnology
  • 6.4. Asia Pacific gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 6.4.1. Academic and Government Research Institutes
    • 6.4.2. Biotechnology and Pharmaceutical Companies
    • 6.4.3. Contract Development and Manufacturing Organisations
    • 6.4.4. Agricultural and Industrial Biotechnology Companies
  • 6.5. Asia Pacific gRNA Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 6.5.1. China gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.2. China gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.3. China gRNA Market Outlook, by Application, 2020-2033
    • 6.5.4. China gRNA Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.6. Japan gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.7. Japan gRNA Market Outlook, by Application, 2020-2033
    • 6.5.8. Japan gRNA Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.10. South Korea gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.11. South Korea gRNA Market Outlook, by Application, 2020-2033
    • 6.5.12. South Korea gRNA Market Outlook, by End User, 2020-2033
    • 6.5.13. India gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.14. India gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.15. India gRNA Market Outlook, by Application, 2020-2033
    • 6.5.16. India gRNA Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.18. Southeast Asia gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.19. Southeast Asia gRNA Market Outlook, by Application, 2020-2033
    • 6.5.20. Southeast Asia gRNA Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO gRNA Market Outlook, by Product Type, 2020-2033
    • 6.5.22. Rest of SAO gRNA Market Outlook, by Grade, 2020-2033
    • 6.5.23. Rest of SAO gRNA Market Outlook, by Application, 2020-2033
    • 6.5.24. Rest of SAO gRNA Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America gRNA Market Outlook, 2020-2033

  • 7.1. Latin America gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 7.1.1. Single Guide RNA
    • 7.1.2. Two-Part crRNA-tracrRNA
    • 7.1.3. Guide RNA Libraries
    • 7.1.4. Custom Design and Synthesis Services
  • 7.2. Latin America gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 7.2.1. Research Grade
    • 7.2.2. High-Purity Preclinical Grade
    • 7.2.3. GMP Grade
  • 7.3. Latin America gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 7.3.1. Basic Research and Target Discovery
    • 7.3.2. Drug Discovery and Screening
    • 7.3.3. Cell Line Engineering and Bioproduction
    • 7.3.4. Therapeutic Development and Clinical Manufacture
    • 7.3.5. Agricultural Biotechnology
  • 7.4. Latin America gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 7.4.1. Academic and Government Research Institutes
    • 7.4.2. Biotechnology and Pharmaceutical Companies
    • 7.4.3. Contract Development and Manufacturing Organisations
    • 7.4.4. Agricultural and Industrial Biotechnology Companies
  • 7.5. Latin America gRNA Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 7.5.1. Brazil gRNA Market Outlook, by Product Type, 2020-2033
    • 7.5.2. Brazil gRNA Market Outlook, by Grade, 2020-2033
    • 7.5.3. Brazil gRNA Market Outlook, by Application, 2020-2033
    • 7.5.4. Brazil gRNA Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico gRNA Market Outlook, by Product Type, 2020-2033
    • 7.5.6. Mexico gRNA Market Outlook, by Grade, 2020-2033
    • 7.5.7. Mexico gRNA Market Outlook, by Application, 2020-2033
    • 7.5.8. Mexico gRNA Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina gRNA Market Outlook, by Product Type, 2020-2033
    • 7.5.10. Argentina gRNA Market Outlook, by Grade, 2020-2033
    • 7.5.11. Argentina gRNA Market Outlook, by Application, 2020-2033
    • 7.5.12. Argentina gRNA Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM gRNA Market Outlook, by Product Type, 2020-2033
    • 7.5.14. Rest of LATAM gRNA Market Outlook, by Grade, 2020-2033
    • 7.5.15. Rest of LATAM gRNA Market Outlook, by Application, 2020-2033
    • 7.5.16. Rest of LATAM gRNA Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa gRNA Market Outlook, 2020-2033

  • 8.1. Middle East & Africa gRNA Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 8.1.1. Single Guide RNA
    • 8.1.2. Two-Part crRNA-tracrRNA
    • 8.1.3. Guide RNA Libraries
    • 8.1.4. Custom Design and Synthesis Services
  • 8.2. Middle East & Africa gRNA Market Outlook, by Grade, Value (US$ Mn), 2020-2033
    • 8.2.1. Research Grade
    • 8.2.2. High-Purity Preclinical Grade
    • 8.2.3. GMP Grade
  • 8.3. Middle East & Africa gRNA Market Outlook, by Application, Value (US$ Mn), 2020-2033
    • 8.3.1. Basic Research and Target Discovery
    • 8.3.2. Drug Discovery and Screening
    • 8.3.3. Cell Line Engineering and Bioproduction
    • 8.3.4. Therapeutic Development and Clinical Manufacture
    • 8.3.5. Agricultural Biotechnology
  • 8.4. Middle East & Africa gRNA Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 8.4.1. Academic and Government Research Institutes
    • 8.4.2. Biotechnology and Pharmaceutical Companies
    • 8.4.3. Contract Development and Manufacturing Organisations
    • 8.4.4. Agricultural and Industrial Biotechnology Companies
  • 8.5. Middle East & Africa gRNA Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 8.5.1. GCC gRNA Market Outlook, by Product Type, 2020-2033
    • 8.5.2. GCC gRNA Market Outlook, by Grade, 2020-2033
    • 8.5.3. GCC gRNA Market Outlook, by Application, 2020-2033
    • 8.5.4. GCC gRNA Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa gRNA Market Outlook, by Product Type, 2020-2033
    • 8.5.6. South Africa gRNA Market Outlook, by Grade, 2020-2033
    • 8.5.7. South Africa gRNA Market Outlook, by Application, 2020-2033
    • 8.5.8. South Africa gRNA Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt gRNA Market Outlook, by Product Type, 2020-2033
    • 8.5.10. Egypt gRNA Market Outlook, by Grade, 2020-2033
    • 8.5.11. Egypt gRNA Market Outlook, by Application, 2020-2033
    • 8.5.12. Egypt gRNA Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria gRNA Market Outlook, by Product Type, 2020-2033
    • 8.5.14. Nigeria gRNA Market Outlook, by Grade, 2020-2033
    • 8.5.15. Nigeria gRNA Market Outlook, by Application, 2020-2033
    • 8.5.16. Nigeria gRNA Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East gRNA Market Outlook, by Product Type, 2020-2033
    • 8.5.18. Rest of Middle East gRNA Market Outlook, by Grade, 2020-2033
    • 8.5.19. Rest of Middle East gRNA Market Outlook, by Application, 2020-2033
    • 8.5.20. Rest of Middle East gRNA Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Integrated DNA Technologies
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Synthego Corporation
    • 9.4.3. Thermo Fisher Scientific Inc.
    • 9.4.4. Merck KGaA
    • 9.4.5. Agilent Technologies, Inc.
    • 9.4.6. GenScript Biotech Corporation
    • 9.4.7. Revvity, Inc.
    • 9.4.8. Aldevron
    • 9.4.9. Twist Bioscience Corporation
    • 9.4.10. TriLink BioTechnologies

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!